Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Monday, October 14, 2013

New trimethylaminuria paper by Preti, Fennessey et al

Individuals Reporting Idiopathic Malodor Production: Demographics and Incidence of Trimethylaminuria.
Wise PM, Eades J, Tjoa S, Fennessey PV, Preti G.

Monell Chemical Senses Center, Philadelphia, Pa.

Individuals with the metabolic disorder trimethylaminuria may sporadically produce malodors despite good hygiene. The psychosocial impact of trimethylaminuria can be considerable. However, trimethylaminuria is difficult to diagnose without specialized tests, in part because odor production is diet-dependent and malodors may not be present during medical examinations. Thus, the prevalence and demographics of trimethylaminuria remain unclear.

We tested 353 patients who had unexplained (idiopathic) malodor production for trimethylaminuria using a standard choline challenge. We also collected basic demographic information.

Approximately one third of patients (118) tested positive for trimethylaminuria. Consistent with previous reports, women, particularly African American women, were significantly overrepresented among trimethylaminuria-positive patients. Of note, the same pattern was seen among trimethylaminuria-negative patients. Also consistent with previous reports, trimethylaminuria-positive women who were still menstruating tended to produce higher levels of trimethylamine within ±7 days of menses, although this trend was statistically marginal (P = .07).

If our patient sample is representative of patients with idiopathic malodor, demographic information (race and gender) may not be useful in a differential diagnosis of trimethylaminuria. However, undiagnosed cases of trimethylaminuria may be fairly common among patients with idiopathic malodor. If so, choline challenge testing should be indicated for all such patients because trimethylaminuria is responsive to dietary and other treatments. We speculate that testing also might reveal cases of trimethylaminuria among those diagnosed with certain psychologic disorders, including olfactory reference syndrome.

This is the abstract of a new paper on trimethylaminuria (TMAU) published ahead of print of the full paper. It could be a paper unfinished from a while ago, since it includes Susan Tjoa as an author, who sadly passed away a few years ago now.

It sounds a very useful paper as evidence for the case of testing most people with a long-time suspected malodor problem, including those diagnosed with the recently defined psychiatric 'disorder' known as 'olfactory reference syndrome'.

Of interest is :
The number of people who 'failed' the test (about 1/3). This was probably under the 'Denver TMAU test reference ranges', which does not seem to regard TMA level alone as significant (and hence is very unlikely to find anyone positive for 'TMA substrate overload' (the most common type of TMAU2).

A large number of the positive cases were women and especially African American women. This seems to be a reflection of the community, although perhaps women are more likely to test. Nevertheless, women of African American descent seem to be over-represented in the community.

They suggest it may be worthwhile testing those diagnosed with 'olfactory reference syndrome' for TMAU. This has been a MEBO Research suggestion for a while now. It would make an excellent study and possibly mark the end of 'ORS'.

They used a choline challange for the test. It would be interesting to have seen the test done using the 'TMAU carrier test' protoco', which involved taking 600mg TMA in a capsule. Normal people would still be able to process almost all of 600mg of TMA, but those with 'no reserve capacity' (probably all 'carriers') would likely show up along with 'sufferers'.

So, all in all, it sounds like an excellent paper as evidence about the prevalence of TMAU using the traditional TMAU testing methods and protocol followed by the Denver lab which has a long association with TMAU.


Post a Comment